Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia

Zugno, Alexandra I.; Chipindo, Helder; Volpato, Ana Maria; Budni, Josiane; Steckert, Amanda V.; Oliveira, Mariana B.; Heylmann, Alexandra S.; Silveira, Flávia da Rosa; Mastella, Gustavo Antunes; Maravai, Soliany Grassi; Wessler, Patricia Gomes; Binatti, A.R.; Panizzutti, Bruna; Schuck, Patrícia Fernanda; Quevedo, Joao L De; Gama, Clarissa Severino

doi:10.1016/j.neuroscience.2013.11.049

Cited by 66 publications

(42 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Beneficial effects of early N-acetylcysteine treatment were shown in a mouse model with chronic GSH deficit [135,136]. In the ketamine model of schizophrenia, omega-3 fatty acids prevented damage of lipids and proteins in the rat brain [137].…”

Section: Animal Studiesmentioning

confidence: 98%

Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism

Smaga

Niedzielska

Gawlik

et al. 2015

Pharmacological Reports

225

123

View full text Add to dashboard Cite

The pathophysiology of psychiatric diseases, including depression, anxiety, schizophrenia and autism, is far from being fully elucidated. In recent years, a potential role of the oxidative stress has been highlighted in the pathogenesis of neuropsychiatric disorders. A body of clinical and preclinical evidence indicates that psychiatric diseases are characterized by higher levels of oxidative biomarkers and with lower levels of antioxidant defense biomarkers in the brain and peripheral tissues. In this article, we review current knowledge on the role of the oxidative stress in psychiatric diseases, based on clinical trials and animal studies, in addition, we analyze the effects of drug-induced modulation of oxidative balance and explore pharmacotherapeutic strategies for oxidative stress reduction.

show abstract

Section: Animal Studiesmentioning

confidence: 98%

Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism

Smaga

Niedzielska

Gawlik

et al. 2015

Pharmacological Reports

225

123

View full text Add to dashboard Cite

show abstract

“…131,132 The use of PUFA, particularly omega-3, is a potential alternative and adjunct to current antipsychotics treatments. Omega-3 fatty acids are effective in reducing oxidative stress in preclinical models 133,134 and dietary supplementation may be beneficial in psychiatric conditions. 135 Omega-3 might be most promising in preventing the transition to psychosis for at-risk mental state subjects.…”

Section: Outlook For Preventive Developmental Therapiesmentioning

confidence: 99%

Targeting Oxidative Stress and Aberrant Critical Period Plasticity in the Developmental Trajectory to Schizophrenia

Q.¹,

Cuénod²,

Hensch

2015

SCHBUL

141

118

View full text Add to dashboard Cite

Schizophrenia is a neurodevelopmental disorder reflecting a convergence of genetic risk and early life stress. The slow progression to first psychotic episode represents both a window of vulnerability as well as opportunity for therapeutic intervention. Here, we consider recent neurobiological insight into the cellular and molecular components of developmental critical periods and their vulnerability to redox dysregulation. In particular, the consistent loss of parvalbumin-positive interneuron (PVI) function and their surrounding perineuronal nets (PNNs) as well as myelination in patient brains is consistent with a delayed or extended period of circuit instability. This linkage to critical period triggers (PVI) and brakes (PNN, myelin) implicates mistimed trajectories of brain development in mental illness. Strategically introduced antioxidant treatment or later reinforcement of molecular brakes may then offer a novel prophylactic psychiatry.

show abstract

“…In line with this, administration of the glutamate receptor antagonist ketamine, has recently been shown to specifically affect mitochondrial respiratory chain complexes [180]. Importantly, the atypical antipsychotic clozapine reverses ketamine induced social isolation rearing (SIR) phenotypes and NMDA receptor antagonist dizocilpine induced deficits in pre-pulse inhibition [181–183]. Illustrating these effects, Moller et al .…”

Section: In Vivo Genetic and Post-mortem Studies Of Patients With Pmentioning

confidence: 99%

Purinergic Signaling and Energy Homeostasis in Psychiatric Disorders

Lindberg¹,

Shan²,

Ayers-Ringler³

et al. 2015

CMM

View full text Add to dashboard Cite

Purinergic signaling regulates numerous vital biological processes in the central nervous system (CNS). The two principle purines, ATP and adenosine act as excitatory and inhibitory neurotransmitters, respectively. Compared to other classical neurotransmitters, the role of purinergic signaling in psychiatric disorders is not well understood or appreciated. Because ATP exerts its main effect on energy homeostasis, neuronal function of ATP has been underestimated. Similarly, adenosine is primarily appreciated as a precursor of nucleotide synthesis during active cell growth and division. However, recent findings suggest that purinergic signaling may explain how neuronal activity is associated neuronal energy charge and energy homeostasis, especially in mental disorders. In this review, we provide an overview of the synaptic function of mitochondria and purines in neuromodulation, synaptic plasticity, and neuron-glia interactions. We summarize how mitochondrial and purinergic dysfunction contribute to mental illnesses such as schizophrenia, bipolar disorder, autism spectrum disorder (ASD), depression, and addiction. Finally, we discuss future implications regarding the pharmacological targeting of mitochondrial and purinergic function for the treatment of psychiatric disorders.

show abstract

Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia

Cited by 66 publications

References 53 publications

Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism

Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism

Targeting Oxidative Stress and Aberrant Critical Period Plasticity in the Developmental Trajectory to Schizophrenia

Purinergic Signaling and Energy Homeostasis in Psychiatric Disorders

Contact Info

Product

Resources

About